Ketamine-Assisted EMDR™ (KA-EMDR) vs MDMA-Assisted Therapy

A side-by-side comparison of recorded mechanisms, evidence review status, related condition topics, and philosophical roots.

At a glance

Source checks, condition-specific assessments and expert review are separate steps. Each assessment applies only to its stated population and use. Topic links do not establish comparative effectiveness.

Ketamine-Assisted EMDR™ (KA-EMDR)

Tradition
Integrative
Founder
Danielle Ciccone & Michele Topel (2024)
Review status
Assessment not yet completed
Focus
Somatic + Cognitive
Format
Individual
Duration
Short to Medium

MDMA-Assisted Therapy

Tradition
Psychedelic
Founder
MAPS / Mithoefer (2021)
Review status
4 source checks available
Official sources
Guidelines and official sources (4)

3 clinical guideline checks · 1 regulatory source check

Read the recommendation and its scope. A source may discuss an approach without recommending it.

  • NDA 215455: midomafetamine complete response letter

    US Food and Drug Administration · 2024-08-08; Reference ID 5427030 · Regulatory source · Complete response issues 1–3, pages 1–4; additional comments pages 5–6

    Not a treatment recommendation

    The letter verifies the 2024 nonapproval decision and identifies safety reporting, durability and bias concerns. Psychotherapy-contribution questions appear separately as additional comments.

    Scope: Midomafetamine application NDA 215455 for PTSD

    Source checked

  • Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder

    VA/DoD · 2023 · Clinical guideline · Recommendation 23; Table 6, p.37

    Insufficient evidence for or against

    VA/DoD finds insufficient evidence for or against MDMA-assisted psychotherapy. The guideline’s evidence cutoff precedes later trials and regulatory decisions.

    Scope: MDMA-assisted psychotherapy for adults with PTSD; evidence reviewed through May 2022.

    Source checked

  • Management of Major Depressive Disorder

    VA/DoD · Version 4.0, February 2022; evidence through January 2021 · Clinical guideline · Recommendation 35; pp.26,67–68

    Recommendation against the stated use

    VA/DoD strongly recommends against MDMA for MDD outside research. This 2022 guideline used evidence through January 2021; it does not assess later trials or every diagnosis.

    Scope: MDMA for MDD outside research settings.

    Source checked

  • Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults

    American Psychological Association · Approved February 2025; 2025 update · Clinical guideline · Psychedelic interventions, printed p.14 (PDF p.18)

    Insufficient evidence for or against

    APA finds insufficient evidence for or against this intervention in the reviewed comparisons.

    Scope: Adults with PTSD; MDMA-assisted psychotherapy versus the inactive or low-dose active comparators reviewed.

    Source checked

Focus
Experiential + Processing
Format
Individual (co-therapist)
Duration
Short (3 sessions)

How they work

Ketamine-Assisted EMDR™ (KA-EMDR)

Core mechanism: Standard 8-phase EMDR protocol adapted for ketamine integration. Client self-administers low-dose sublingual ketamine (troches) at a strategically timed point during the reprocessing phases. The psycholytic dose is intended to expand the window of tolerance and enhance neuroplasticity while preserving the client's capacity to engage in bilateral stimulation and verbal processing, unlike higher-dose psychedelic approaches that impair interactive participation.

Ontology: Traumatic memories are stored in maladaptive neural networks (per EMDR's Adaptive Information Processing model). Low-dose ketamine enhances neuroplasticity and the memory reconsolidation window, allowing EMDR's bilateral stimulation to reprocess traumatic material more effectively. The pharmacological and psychotherapeutic mechanisms are proposed as synergistic rather than additive.

MDMA-Assisted Therapy

Core mechanism: MDMA reduces the fear response and increases trust and empathy, making it possible to stay with trauma material inside the therapeutic relationship

Ontology: PTSD maintained by overwhelming fear that prevents therapeutic engagement; MDMA lowers this barrier pharmacologically

Related condition topics

These editorial cross-references organize reading. A shared link does not mean both approaches are effective, recommended, or interchangeable for that condition.

1 shared · 0 Ketamine-Assisted EMDR™ (KA-EMDR)-only · 1 MDMA-Assisted Therapy-only

Linked to both entries

Linked only in the MDMA-Assisted Therapy entry

What each assumes — and misses

Ketamine-Assisted EMDR™ (KA-EMDR)

Philosophical roots: Inherits EMDR's basis in information processing theory and memory reconsolidation science. The ketamine component draws on psycholytic therapy tradition (Passie et al., 2022): the use of sub-psychedelic doses to enhance psychotherapeutic process rather than induce altered states as the primary intervention.

Blind spots: Rests on a single uncontrolled pilot study with no comparator, run by the modality's own developers; requires the client to self-administer a Schedule III dissociative anesthetic mid-session rather than have it clinician-administered; the protocol name is trademarked and taught only through the founders' own institute, the same training-revenue structure flagged elsewhere on this site; combines two modalities, ketamine and EMDR's bilateral stimulation, whose interaction has not been independently studied, so the claimed synergy between pharmacological and psychotherapeutic mechanisms is a hypothesis, not a finding

Therapeutic voice: The dose is low on purpose. You should still be able to talk to me and follow the tapping, and if it gets to be too much we stop the set and stay with the breathing until you're back.

MDMA-Assisted Therapy

Philosophical roots: Mithoefer (inner healing intelligence); Rogers (organismic wisdom, given conditions); Buber (I-Thou enabled pharmacologically); trauma processing theory

Blind spots: FDA declined approval (2024); methodological concerns about unblinding; not currently legally available outside research

Therapeutic voice: You're safe here. If something difficult comes up, you can move toward it. You don't have to do this alone.

Choosing between them

Ketamine-Assisted EMDR™ (KA-EMDR) (Integrative) and MDMA-Assisted Therapy (Psychedelic) come from different traditions, which means they assume different things about what a person is, what causes suffering, and what the therapeutic relationship is for. The choice between them is often less about "which works better" and more about which set of assumptions fits the client and the therapist.

For deeper coverage: see the full Ketamine-Assisted EMDR™ (KA-EMDR) and MDMA-Assisted Therapy pages, or use the interactive comparison tool to add more modalities to this comparison.